CardioNet, Inc. Announces Pricing of Secondary Offering of Common Stock
August 01 2008 - 8:26AM
Business Wire
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with an initial focus on the diagnosis and
monitoring of cardiac arrhythmias, today announced the pricing of
5,000,000 shares of outstanding common stock being offered by
certain existing stockholders to the public at the price of $26.50
per share. CardioNet, Inc. will not receive any proceeds from the
sale. The offer is expected to close on August 6, 2008. The selling
stockholders have also granted to the underwriters a 30-day option
to purchase from them an additional 750,000 shares to cover
over-allotments, if any. Citi is the sole book-running manager,
Banc of America Securities LLC and Leerink Swann are the co-lead
managers and Cowen and Company and Thomas Weisel Partners LLC are
the co-managers for this offering. A registration statement
relating to these securities was declared effective by the
Securities and Exchange Commission on July 31, 2008. This offering
is being made by the existing stockholders solely by means of
written prospectus. Copies of the final prospectus relating to the
offering may be obtained, when available, by contacting the
Prospectus Department of Citi by calling (800) 831-9146, by
emailing batprospectusdept@citigroup.com or by writing to Brooklyn
Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220 or at
the Securities and Exchange Commission�s website:
http://www.sec.gov. This communication shall not constitute an
offer to sell or the solicitation of an offer to buy nor shall
there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state.
Statements in this press release that are not strictly historical
are �forward-looking� statements within the meaning of the Private
Securities Litigation Reform Act of 1995 and involve a high degree
of risk and uncertainty. In particular, due to market conditions or
otherwise, the selling stockholders may be unable to complete the
sale of common stock under the registration statement, and, even if
such sale is completed, the underwriters for the offering may not
exercise any portion of the over-allotment option. About CardioNet
CardioNet, Inc. is a leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant
and timely clinical information regarding an individual�s health.
CardioNet�s initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias with a solution that it markets
as the CardioNet System. More information can be found at
http://www.CardioNet.com.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024